Loading asset research
Q3 2026 earnings · Nov 3
AnaptysBio Inc. Common Stock
ANABNasdaq · USD · StocksQuote as of · Exchange session not verified$51.00
-1.35%
Today
ANAB
Loading 1D prices…
Market cap
$1.5B
Volume
437.7K
52w high
$72.3652w low
$13.86Company profile
AnaptysBio Inc. Common Stock
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
San Diego, CA, United States
Employees
104
Fiscal year end
0630
CIK
1370053
Session & valuation
Open$52.38
Previous close$51.70
Day high$52.38
Day low$50.80
30-day avg. volume473.7K
Outstanding shares29.9M
Diluted EPS-$0.44
Latest annual period
P/E (trailing)-115.91
P/E (forward)9.33
Price / book117.77
Beta0.41
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| TYRATyra Biosciences Inc. Common Stock | $1.5B | $0.00 | — | -$2.01 | -3.08% | Buy |
| KLRAKailera Therapeutics Inc. Common Stock | $1.6B | $0.00 | — | -$1.26 | -6.39% | Buy |
| SNDXSyndax Pharmaceuticals Inc. Common Stock | $1.6B | $172.4M | -165.59% | -$3.29 | +1.28% | Buy |
| INVAInnoviva Inc. Common Stock | $1.5B | $411.3M | +65.92% | $3.30 | +0.44% | Hold |
| AVBPArriVent BioPharma Inc. Common Stock | $1.5B | $0.00 | — | -$4.32 | -5.48% | Buy |